Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

NCT01655693 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

397

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Doxorubicin 20 mg/m2
DRUG: Doxorubicin 30 mg/m2
DRUG: Best Standard of Care

Sponsor

Valerio Therapeutics